Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:

##STR00001##

wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

The present invention relates to a composition comprising cyclosporine A (CsA) for use in the prevention of bronchiolitis obliterans syndrome (BOS) in a double lung transplanted patient, or for the treatment of BOS or for the prevention or delay of the progression of BOS in a double lung transplanted patient being diagnosed with BOS, wherein the composition is administered to said patient by inhalation of said composition in aerosolized form comprising a therapeutically effective dose of cyclosporine A.

Methods are disclosed for treating an acute respiratory distress syndrome, such as an acute respiratory distress syndrome associated with a viral infection, such as SARS-CoV2 (COVID-19) in a subject in need thereof. These methods include administering to the subject a pharmaceutical preparation comprising isolated matrix bound vesicles (MBV) derived from extracellular matrix.

The present application relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The application provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases.

The present invention provides supramolecular filament and/or sphere compositions and their use as inhalable drug carriers within aerosols. The invention provides insights into peptide designs and supramolecular stability and its crucial role in the interfacial stability and aerosolization properties of the supramolecular filament and/or sphere compositions. The compositions and their properties show that molecular enrichment at the air-liquid interface during nebulization is the primary factor to deplete the monomeric peptide amphiphiles in solution, accounting for the observed morphological disruption/transitions. Importantly, encapsulation of drugs and dyes within the inventive filament and/or sphere compositions notably stabilize their supramolecular structure during nebulization, and the loaded filaments exhibit a linear release profile from a nebulizer device. The compositions disclosed herein can be used as an effective platform for the inhalation-based treatment of many lung and sinusoidal diseases.

A composition from Traditional Chinese Medicine (TCM) ingredients makes it possible to treat those infected with a virus, including, e.g., coronavirus or the flu, including but not limited to COVID-19 or Influenza A (“FluA”). Although makeable by other methods, the composition is makeable from a decoction of the TCM ingredients. Although usable for other purposes, the composition may be used to treat a patient in need of treatment for a virus, e.g., coronavirus infection, such as COVID-19 infection, or, e.g., the flu, such as FluA, by administering to the patient an effective amount of the composition.

The invention relates to methods for generating an aerosol by nebulization of a composition comprising polyclonal immunoglobulin (Ig). The selection of an efficient membrane nebulizer and a composition optimized for nebulization with such membrane nebulizer results in a particularly efficient method of generating an aerosol for administration of Ig to the respiratory tract.

Disclosed herein are compositions for treating a non-eosinophilic inflammation or inflammatory disorder. The compositions comprise a cannabinoid encapsulated in a drug vehicle. The compositions can be aerosolized for delivery into all pulmonary spaces of a subject in need thereof. The compositions can be used to treat pulmonary inflammatory conditions, including severe asthma (SA), non-eosinophilic asthma, and neutrophilic asthma.

A hydrogen generator electrically coupled to a cloud monitoring system comprises a hydrogen generating device, a monitoring device, a network device, and a controlling device. The monitoring device monitors the machine condition of the hydrogen generating device and generates a condition signal. The network device selectively transmits a machine information including the condition signal to the cloud monitoring system. The controlling device receives an operating parameter from the cloud monitoring system via the network device and controls the hydrogen generating device according to the operating parameter. The hydrogen generator monitoring system of the present invention collects the relevant data of the user using the hydrogen generator and tracks the health status of the user to perform big data analysis.

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.